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EDITORIAL
Summary  of  the  Eleventh  Eilat  Conference  on  New
Antiepileptic Drugs  and  inauguration  of  Editors’
Choice Open  Access  Articles  in  Epilepsy  Research
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PThe  lead  article  in  this  issue  by  Bialer  and  colleagues
is a  summary  of  the  Eleventh  Eilat  Conference  on  New
Antiepileptic Drugs  and  once  again  provides  a  comprehen-
sive progress  report  on  new  antiepileptic  drugs.  This  is  the
10th such  progress  report  from  the  Eilat  conferences  to
appear in  the  pages  of  Epilepsy  Research  since  1995.  The
summary in  this  issue  focuses  only  on  the  preclinical  and
clinical pharmacology  of  AEDs  that  are  currently  in  devel-
opment but  have  not  yet  been  approved  for  marketing.
These include  brivaracetam,  2-deoxy-glucose,  anaxolone,
ICA-105665, imepitoin,  NAX  801-2,  perampanel  and  other
AMPA receptor  antagonists,  tonabersat,  valnoctamide  and
its homologue  sec-propylbutylacetamide  (SPD),  VX-765  and
YK3089.
In a  sense  antiepileptic  drug  development  represents  a
prime example  of  translational  research  in  epilepsy,  which
is a  focus  of  Epilepsy  Research.  No  drug  can  be  tested
in humans  without  adequate  evidence  of  its  efﬁcacy  and
safety in  animal  models.  These  data  must  then  be  trans-
lated into  human  studies,  ﬁrst  of  their  safety  and  then
of both  safety  and  efﬁcacy,  before  coming  to  market.  But
translational research  in  antiepileptic  drug  development
begins even  earlier  than  pre-clinical  studies  of  putative
antiepileptic drugs.  It  begins  with  an  understanding  of  basic
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Open access under CC BY-NC-ND license. echanisms  underlying  seizure  generation  and  the  develop-
ent of  epilepsy.  It  also  extends  further  than  just  bringing
 drug  to  market.  Clinical  and  epidemiological  studies  of
ew drugs  and  their  use  are  all  part  of  the  translational
esearch spectrum  in  epilepsy,  as  applied  to  new  drug  devel-
pment.
In this  issue  we  inaugurate  a  new  feature  of  Epilepsy
esearch. From  time  to  time  the  editors  will  designate
n article  as  an  Editors’  Choice  Open  Access  Article.  Arti-
les selected  for  this  designation  will  be  those  the  editors
elieve are  of  particular  importance  and  of  broad  inter-
st to  the  epilepsy  community.  Designation  as  an  Editors’
hoice Open  Access  Article  will  result  in  electronic  access
o the  speciﬁc  article  without  charge,  even  without  a  sub-
cription to  Epilepsy  Research,  through  the  journal  website
ww.epires-journal.com. It  is  our  pleasure  to  designate
‘Progress  Report  on  New  Antiepileptic  Drugs:  A  Summary
f the  Eleventh  Eilat  Conference  on  new  Antiepileptic  drugs
EILAT XI)’’  by  M.  Bialer,  S.  I.  Johannessen,  R.  H.  Levy,  E.
erucca, T.  Tomson,  and  H.  S.  White  as  our  ﬁrst  ‘‘Editors’
hoice Open  Access  Article.’’
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